TOOKAD

ApprovedSmall molecule

SSteba Biotech S.A.

TOOKAD is one of 60 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

Prostate CancerActive, not recruiting

Erectile DysfunctionApproved

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

TOOKAD

SSteba Biotech S.A.

Approved

4 2

Novantrone

Pfizer

Preclinical

5 3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

Completed·SSteba Biotech S.A.·Phase 3·NCT01875393·81 enrolled

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Completed·SSteba Biotech S.A.·Phase 3·NCT01310894·413 enrolled

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Active, not recruiting·SSteba Biotech S.A.·Phase 2·NCT03315754·50 enrolled

Show 1 more trial

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Withdrawn·SSteba Biotech S.A.·Phase 3·NCT04225299

Erectile Dysfunction1 trial

Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Terminated·SSteba Biotech S.A.·Phase 4·NCT03849365·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TOOKAD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TOOKAD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TOOKAD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Steba Biotech S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSteba Biotech S.A.

TOOKAD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer4 trials

Erectile Dysfunction1 trial

References

Drug Info

Quick Facts

Related News